(175)(173)Free Cash Flow
,550Reconciliation of GAAP EPS Guidance to "Adjusted" EPS Guidance for the Year Ending December 31, 2013(Unaudited)2013GAAP diluted EPS guidance$
.89Known adjustments to arrive at "Adjusted" earnings*:Acquisition-related expenses
0.53Charges associated with cost savings initiatives0.04Stock option expense0.02Expense related to various legal proceedings0.02Non-cash interest expense associated with our convertible notes0.01Other tax adjustments
(0.06)"Adjusted" diluted EPS guidance$
7.45*The known adjustments are presented net of their related tax impact which amount to approximately $0.25 per share in the aggregate. (a)
To exclude acquisition-related expenses related primarily to non-cash amortization of intangible assets and expense resulting from changes in the estimated fair values of the contingent consideration obligations related to prior year business combinations.(b)
To exclude the income tax impact from resolving certain non-routine transfer-pricing and acquisition-related issues with tax authorities as well as the impact related to certain prior period items excluded from adjusted earnings.On October 1, 2013, we acquired Onyx Pharmaceuticals. Many of the adjustments from this transaction have not been determined.
As a result, we expect significantly more adjustments in the fourth quarter that are not included in the table above. Reconciliation of GAAP Tax Rate Guidance to "Adjusted" Tax Rate Guidance for the Year Ending December 31, 2013(Unaudited)2013 with
PR excise tax credit2013 without
PR excise tax creditGAAP tax rate guidance6%
12%Tax rate effect of known adjustments discusse
Copyright©2012 PR Newswire.
All rights reserved